Monographie - Caffeine citrate

Última actualización :
03/05/2024

Caffeine citrate

Factores que influyen sobre la estabilidad

Estructura química

Nombre comercial

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Cafcit	Estados Unidos de América
Cafeina 25% Bioquim	Argentina
Cafeina citrato	España
Cafeina Fada	Argentina
Cafeine citrate Biomed	Nueva Zelanda
Cafeine Sterop	Bélgica
Cafeinnova	Colombia
Caffeinospire	Egipto
Cafirate	India
Citrate de caféine Cooper	Francia
Peyona oral y para perfusion	España
Peyona oral/parenteral	Alemania, Rumania, Turquía

Bibliografía : Caffeine citrate

	Tipo	Publicación
43	Periódico	Fraser BD, Berod T, Whitney HAK. Stability of caffeine citrate injection in polypropylene syringes at room temperature. Am J Health-Syst Pharm 1997 ; 54: 1106-1108.
318	Periódico	Donnelly RF, Tirona RG. Stability of citrated caffeine injectable solution in glass vials. Am J Hosp Pharm 1994 ; 51: 512-514.
691	Periódico	Nahata MC, Zingarelli JR, Durell DE. Stability of caffeine citrate injection in intravenous admixtures and parenteral nutrition solutions. J Clin Pharm Ther 1989 ; 14: 53-55.
1802	Periódico	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
2087	Periódico	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
3379	Periódico	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3644	Laboratorio	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3976	Periódico	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4319	Periódico	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Periódico	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4419	Periódico	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4543	Periódico	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4603	Periódico	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Periódico	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales